Drugs / HRG80
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04932265 | Sep 2021 → Dec 2024 | — | EuroPharma, Inc. | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRG80 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04932265 ↗ |
| Known as | HRG80 Red Ginseng | “HRG80™ Red Ginseng” NCT04932265 ↗ |
| Route | Oral | “after oral administration of two different formulations of HRG80” NCT04932265 ↗ |